Radiopharmaceutical manufacturer International Isotopes has begun producing thallium 201 at both its completed linear accelerator and its cyclotron facilities in Denton, TX. The firm expects that the production of thallium at both facilities will allow
Radiopharmaceutical manufacturer International Isotopes has begun producing thallium 201 at both its completed linear accelerator and its cyclotron facilities in Denton, TX. The firm expects that the production of thallium at both facilities will allow it to provide an ample supply of the isotope to hospitals and clinics in the U.S. Since it is situated near two airports, International Isotopes can ship isotopes with short half-lives overnight, according to Dr. Ira Lon Morgan, chairman and CEO. Thallium has a half-life of 73 hours and is used for the diagnosis of heart disease.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.